Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

Published:2016-11-03 Issue:12 Volume:18 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

García Jorge,Santomé Lucia,Anido Urbano,Fernández-Calvo Ovidio,Afonso-Afonso Javier,Lázaro Martín,Medina Ana,Vázquez Estévez Sergio

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11912-016-0556-3.pdf

Reference84 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.

2. Kogevinas M, Mannetje AT, Cordier S, Ranft U, González CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2003;14(10):907–14.

3. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6-S4):193–8.

4. Blick C, Hall P, Pwint T, Al‐Terkait F, Crew J, Powles T, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder. Cancer. 2012;118(16):3920–7.

5. Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A, et al. Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–46.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma;Cancers;2021-12-12

2. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma;Clinical Genitourinary Cancer;2020-12

3. Malignant Tissue Optical Properties;Multimodal Optical Diagnostics of Cancer;2020

4. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial;The Lancet Oncology;2017-05

5. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment;Immunotherapy;2017-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3